期刊文献+

JAK2V617F基因突变在骨髓增殖性肿瘤诊断中的应用 被引量:3

Application of JAK2V617F mutation to diagnosis of myeloproliferative neoplasms
下载PDF
导出
摘要 目的采用等位基因特异性PCR(AS-PCR)检测骨髓增殖性肿瘤(MPN)中JAK2V617F基因突变,探讨其在MPN诊断中的应用价值。方法回顾性分析452例MPN患者的临床表现与JAK2V617F突变检测结果,结合血常规、骨髓及外周血形态分类等实验室检查,分析JAK2V617F突变与MPN患者临床特征的相关性,以及对MPN诊断和鉴别诊断的作用。结果 452例MPN患者JAK2V617F突变型有293例,总体阳性率64.8%。其中真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)突变的阳性率分别为75.0%、59.5%和46.7%。PV组JAK2V617F突变阳性率明显高于其他两组。293例突变阳性患者中,脾脏肿大170例,骨髓增生极度活跃和明显活跃156例,比例均高于突变阴性患者,差异有统计学意义。PV患者中JAK2V617F突变组的白细胞(WBC)和血小板(Plt)数量高于野生组,差异有统计学意义;ET患者中JAK2V617F突变组的WBC和Hb含量高于野生组,差异有统计学意义。PMF患者中JAK2V617F突变组与野生组比较,差异无统计学意义。结论 AS-PCR能快速准确检测出JAK2V617F基因突变,其突变率与疾病类型和患者临床资料相关。 【Objective】To detect the JAK2V617 F mutation in myeloproliferative neoplasms(MPN) by allelespecific PCR(AS-PCR) and explore the diagnostic value of JAK2V617 F mutation in MPN. 【Methods】 The clinical manifestations and results of JAK2V617 F mutation were reviewed from 452 cases diagnosed as MPN.Combined with the blood routine, bone marrow morphology and other results of laboratory tests, the relationship between JAK2V617 F mutation and clinical characteristics and their roles for the diagnosis and differential diagnosis of MPN were analyzed. 【Results】 Of the 452 cases, 293 had JAK2V617 F mutation, the total frequency was 64.8%. The mutation frequency was 75.0% among the patients with polycythemia vera(135 / 180),59.5% among the patients with essential thrombocythemia(21 / 93) and 46.7% among the patients with primary myelofibrosis(14 / 30). The frequency of JAK2V617 F mutation was significantly higher in the patients with polycythemia vera than those with other two diseases. Among the 293 cases with mutation-type JAK2V617 F,170 cases had splenomegaly, 156 cases had hyperactivity of bone marrow and apparently active proliferation,the frequency was significantly higher than the cases with wild-type JAK2. The polycythemia vera patients with mutation-type JAK2V617 F had statistically higher leukocyte and platelet count than those with wild-type JAK2. The essential thrombocythemia patients with mutation-type JAK2 had significantly higher leukocyte count and hemoglobin content than those with wild-type JAK2. Compared to the primary myelofibrosis patients with wild-type JAK2, those with mutation-type JAK2 had no significant difference in leukocyte count,platelets count or hemoglobin content. 【Conclusions】 AS-PCR can rapidly and accurately detect JAK2V617 F mutation, and the mutation frequency has a relationship with the type of MPN and the clinical data of the patients.
出处 《中国现代医学杂志》 CAS 北大核心 2015年第26期46-49,共4页 China Journal of Modern Medicine
关键词 骨髓增殖性肿瘤 JAK2V617F突变 等位基因特异性PCR 血细胞计数 myeloproliferative neoplasm JAK2V617F mutation allele-specific PCR blood cell count
  • 相关文献

参考文献6

二级参考文献42

  • 1费海荣,张日,陈苏宁,潘金兰,岑建农,薛永权.骨髓增殖性疾病137例患者JAK2基因突变的研究[J].中华内科杂志,2007,46(4):271-273. 被引量:15
  • 2Tefferi A ,Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel [J]. Blood, 2007, 110 (4) : 1092 -1097.
  • 3James C, Ugo V, Couedic JPL, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera [ J ]. Nature, 2005, 434 (7037) : 1144 -1148.
  • 4Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myelopmliferative diseases [J]. Lancet, 2005, 365 (9464): 1054-1061.
  • 5Kralovics R, Passamonti F, Buser AS, et al. Again - of - function mutation of JAK2 in myelopmliferative disorders [ J ]. N Engl J Med, 2005, 352:1779 - 1790.
  • 6Talarico L, Wolf BC, Kumar A, et al. Reversal bone marrow fibrosis and subsequent development of polycythemia in patients with myeloproliferative disorders [J]. Am J Hematol, 1989, 30 (4) : 248 -253.
  • 7Jantunen R, Juvonen E, Ikkala E, et al. Development of erythrocytosis in the course of essential thrombocythemia [J]. Ann Hematol, 1999, 78 (5): 219-222.
  • 8Randi ML, Fabris F, Girolami A. Leukemia and myelodysPlasia effect of multiple cytotoxic therapy in essential thrombocythemia [ J ]. Leuk Lymphoma, 2000, 37 (3/4): 379-85.
  • 9Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutationin JAK2 is associated with poorer survival inidiopathie myelofibrosis [ J]. Blood, 2005, 107 (5): 2098-2100.
  • 10Mesa RA, PowellH, LashoT, etal. JAK2 (V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia [ J ]. Leuk Res, 2006, 30 (11): 1457-1460.

共引文献22

同被引文献17

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部